Laura Travis, APRN
Family · Lexington, KYNPI 1013495605
Payments from drug & device makers
Across 610 payments — averaging $17.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- AbbVie$2K
- Johnson & Johnson$954
- Takeda Pharmaceuticals U.S.A., Inc.$892
- Gilead$536
- Sanofi$454
- plus $4K from 28 others
What the payments were for
- Food & beverage$10,35399%
- Education$1191%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 145 | $2,288 |
| AbbVie | 100 | $1,765 |
| Johnson & Johnson(2 entities) | 55 | $954 |
| Takeda Pharmaceuticals U.S.A., Inc. | 52 | $892 |
| Gilead | 30 | $536 |
| Sanofi | 28 | $454 |
| Regeneron Healthcare Solutions, Inc. | 19 | $377 |
| QOL Medical, LLC | 19 | $353 |
| Pfizer | 21 | $342 |
| Ironwood Pharmaceuticals, Inc | 16 | $286 |
| Bristol Myers Squibb | 16 | $284 |
| Intercept Pharmaceuticals, Inc. | 14 | $233 |
| Ardelyx, Inc. | 12 | $207 |
| Lilly USA, LLC | 10 | $205 |
| Phathom Pharmaceuticals, Inc. | 19 | $200 |
| Nestle Healthcare Nutrition Inc. | 10 | $171 |
| Janssen Scientific Affairs, LLC | 1 | $145 |
| Braintree Laboratories, Inc. | 7 | $108 |
| Merck | 6 | $98 |
| Evoke Pharma, Inc. | 5 | $88 |
| Aimmune Therapeutics, Inc. | 3 | $75 |
| Boehringer Ingelheim | 4 | $72 |
| Medtronic | 1 | $62 |
| Fresenius Kabi USA, LLC | 4 | $60 |
| Ferring Pharmaceuticals Inc. | 2 | $49 |
| Madrigal Pharmaceuticals | 2 | $32 |
| Organon | 2 | $30 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
| Amgen | 1 | $16 |
| Celltrion USA Inc. | 1 | $16 |
| Ipsen Biopharmaceuticals, Inc | 1 | $15 |
| Pharmacosmos Therapeutics Inc. | 1 | $15 |
| AMAG Pharmaceuticals, Inc. | 1 | $14 |
| Redhill Biopharma Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- STELARA$145
How this compares
$10,472 in reported general payments places this provider in the 95th percentile of 4,374 family providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 20 | $558,898 |
| SucraidSacrosidase | 34 | $303,842 |
| CreonLipase/Protease/Amylase | 74 | $258,646 |
| XifaxanRifaximin | 75 | $224,226 |
| RezdiffraResmetirom | 24 | $96,837 |
| LinzessLinaclotide | 102 | $81,266 |
| RelistorMethylnaltrexone Bromide | 23 | $53,363 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 202 | $34,479 |
| IbsrelaTenapanor Hcl | 13 | $26,188 |
| Dexlansoprazole DrDexlansoprazole | 32 | $14,696 |
| Ursodiol | 39 | $13,592 |
| MotegrityPrucalopride Succinate | 20 | $12,334 |
| Mesalamine | 21 | $9,084 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 111 | $7,075 |
| MovantikNaloxegol Oxalate | 17 | $6,931 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $954 | $558,89820 claims |
| AbbVieCreon, Linzess | $1,765 | $339,912176 claims |
| QOL Medical, LLCSucraid | $353 | $303,84234 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Relistor | $2,288 | $277,58998 claims |
| Madrigal PharmaceuticalsRezdiffra | $32 | $96,83724 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $49 | $34,479202 claims |
| Ardelyx, Inc.Ibsrela | $207 | $26,18813 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $892 | $12,33420 claims |
| Redhill Biopharma Inc.Movantik | $12 | $6,93117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,374 family providers in Kentucky.
Other family in Lexington
- Elizabeth SaltLexington$89K
- Alisha ClemonsLexington$55K
- Timothy SmallwoodLexington$27K
- Lauren MaupinLexington$18K
- Angela CrutcherLexington$16K
- Emily MesserliLexington$13K
- Rhiannon BlackLexington$12K
- Bonnie HillLouisa$372K
- Ashley SnellenElizabethtown$190K
- Smita RanjanLouisville$92K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.